Diabetes and cardiovascular franchise
Sanofi’s (SNY) diabetes and cardiovascular portfolio includes Lantus, Toujeo, Multaq, and Praluent. These drugs reported revenues of 1.67 billion euros for 3Q17, representing a 9.1% YoY (year-over-year) fall in operating revenues, including revenues from emerging markets.
Excluding revenues from emerging markets, the franchise reported revenues of 1.30 billion euros for 3Q17—a 14.8% YoY decline.
SNY’s cardiovascular products include Multaq and Praluent. The combined revenues for these drugs was 123 million euros in 3Q17, or 4% higher YoY, including revenues from emerging markets.
If we exclude revenues from emerging markets, Multaq sales fell 4.6% to 80 million euros in 3Q17, while Praluent sales rose 26.5% to 41 million euros.
SNY’s diabetes products include Lantus and Toujeo. Diabetes products reported revenues of 1.55 billion euros in 3Q17, or 10% lower YoY, including revenues from emerging markets. If we exclude emerging markets sales, diabetes products reported revenues of 1.18 billion euros for 3Q17—a 16.3% YoY fall.
Lantus reported revenues of 867 million euros for 3Q17, which was 22% lower YoY, excluding emerging market sales. This fall was driven by lower sales from the US and in European markets.
Toujeo reported revenues of 179 million euros in 3Q17—14% higher YoY—excluding emerging market sales. This growth was driven by strong sales from all major markets outside the US.